Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 7.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,017,180 shares of the biopharmaceutical company’s stock after buying an additional 73,107 shares during the quarter. Celgene Corporation accounts for about 2.7% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s investment portfolio, making the stock its 10th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.13% of Celgene Corporation worth $137,736,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation during the first quarter valued at approximately $118,000. Penserra Capital Management LLC bought a new position in shares of Celgene Corporation during the second quarter valued at approximately $129,000. Acropolis Investment Management LLC bought a new position in shares of Celgene Corporation during the second quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the last quarter. Finally, Rational Advisors LLC bought a new position in shares of Celgene Corporation during the second quarter valued at approximately $156,000. 79.39% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ:CELG) opened at 98.17 on Monday. The firm has a market capitalization of $76.80 billion, a P/E ratio of 30.40 and a beta of 1.89. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The firm’s 50-day moving average price is $136.88 and its 200 day moving average price is $129.95.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the prior year, the company earned $1.58 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. Analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
A number of research analysts have recently commented on CELG shares. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 target price on the stock. in a research note on Tuesday, August 29th. Leerink Swann reissued a “buy” rating and issued a $156.00 price objective on shares of Celgene Corporation in a research note on Friday, October 20th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. Morgan Stanley dropped their price objective on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Celgene Corporation in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene Corporation currently has a consensus rating of “Buy” and a consensus price target of $139.77.
In other news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock valued at $6,268,259 over the last ninety days. Corporate insiders own 0.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Stake Lifted by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/10/30/celgene-corporation-celg-stake-lifted-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.